Molecular basis of SARS-CoV-2 proofreading enzyme-mediated resistance to remdesivir.
Yang, Y., Li, Y., Becker, S.T., Khan, A., Luo, G., Liu, B., Liu, C.(2025) Proc Natl Acad Sci U S A 122: e2519755122-e2519755122
- PubMed: 41032524 
- DOI: https://doi.org/10.1073/pnas.2519755122
- Primary Citation of Related Structures:  
9Q1J - PubMed Abstract: 
SARS-CoV-2's remarkable resistance to nucleotide analog antivirals such as remdesivir, which thwarts RNA synthesis by inhibiting viral polymerase (RdRp), challenges available therapies. We reveal that remdesivir incorporation destabilizes RdRp-RNA complex while enhancing RNA binding to the proofreading exoribonuclease (ExoN), facilitating remdesivir excision. Conserved ExoN determinants for remdesivir recognition and excision underpin ExoN-mediated resistance across all coronaviruses. These findings inform the design of next-generation antivirals and combination therapies capable of overcoming ExoN-mediated resistance.
- Roy J. Carver Department of Biochemistry, Biophysics and Molecular Biology, Iowa State University, Ames, IA 50011.
Organizational Affiliation: 



















